Rexgene Biotech Co., Ltd.

Insider

First SEC filing: Nov. 30, 2007 · Latest: Nov. 30, 2007

On this page

Insider at

0 buys (P) 0 sells (S) Net: $0 + 2 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

No open-market trades on record; showing all filings.

Date	Ticker	Code	Shares	Price	Value	Owned after	Δ own	A/D	vs now
Dec. 24, 2007	IRD	A	142,857	—	—	142,857 Direct	—	Acquired	(price as of 2026-08-20)
Dec. 24, 2007	IRD	A	714,286	$1.40	$1,000,000	5,505,956 Direct	+14.91%	Acquired	-99.4% (price as of 2026-08-20)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Options, RSUs and convertible securities reported on Form 4 Table II.

Date	Ticker	Security	Underlying	Exercise price	Expiration	Shares	A/D
Dec. 24, 2007	IRD	Warrant (Right to Buy)	Common Stock (142,857)	$1.80	Dec. 24, 2010	142,857	Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Securities held when first becoming an insider, per SEC Form 3.

Date	Ticker	Security	Shares	Ownership
Nov. 30, 2007	IRD	Common Stock, par value $.0001	4,791,670	Direct
Nov. 30, 2007	IRD	Securities Purchase Agreement (right to purchase) [F1]→ Common Stock [F1] (714,286)	714,286	Direct
Nov. 30, 2007	IRD	Securities Purchase Agreement (right to purchase) [F1]→ Warrant to Purchase Common Stock [F1] (142,857)	142,857	Direct
May 17, 2005	IRD	Common Stock [F1]	4,791,670	Direct